TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Subjective symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear evaporation decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total medial tibiofemoral BML volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knowledge of FV portion sizes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: peritoneal release of tryptase and chymase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of postoperative ileus (POI)
Endpoint domain: Adverse events/effects
Primary endpoint: Abstinence rate at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Objective continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: lower leg volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of new MA development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression rates of new MA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: single-procedure freedom from atrial tachyarrhythmia (ATA)
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to cross the aortic valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncorrected visual acuity at 3 months postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse rate of panic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trocar placement precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts to position the trocar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause mortality at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Dislocation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Revision rates
Endpoint domain: Adverse events/effects
Primary endpoint: Total PSA, free‐PSA ratio and PSA density diagnostic characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary event occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Transition Dyspnea Index improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Arterial blood oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain score
Endpoint domain: Adverse events/effects
Primary endpoint: EBC Cl(‐) secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sensory dermatomes affected by thoracic paravertebral blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of strokes and other cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AMP PC(20) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: performance level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-4 anemia, granulocytopenia, and thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: mean time of first request of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttest scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Likelihood of using the program again
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Enjoyment of the program
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to reach an oxygen saturation of 92%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preinduction oxygen tensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in psychological symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in visual vertigo symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: geriatric depression score (GDS 15)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Oxygen dependency at 36 weeks postmenstrual age or death
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: persistent loco-regional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year probability of subsequent DM
Endpoint domain: Mortality/survival
Primary endpoint: CytOx signal predicting brain damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Impaired neuropsychological outcome
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity of dobutamine stress echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity of adenosine echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of persistent symptoms after echocardiography
Endpoint domain: Adverse events/effects
Primary endpoint: net adverse effect (global index)
Endpoint domain: Adverse events/effects
Primary endpoint: Successful weaning from nCPAP during the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epigastric pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: knowledge, attitude and preventive practice behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: COX-2 expression in monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-6 secretions of monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for renal replacement therapy
Endpoint domain: Adverse events/effects
Primary endpoint: urine output postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum ECP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: gait initiation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: A1C levels over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Risk of GDM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: grade 2 or greater corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: dryness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area of newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: creatinine clearance at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: event-free survival after 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Folic acid absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Folate rate constant of elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: age-adjusted 31-electrode mean VL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in KCCQ overall summary score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: All-cause mortality/hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Sustained unresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median peanut-specific IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: highest SaO2 during operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: proportion of maximum chest rise movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Penetration of Capasio into dentinal tubules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apatite deposition by Capasio and MTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deaths from bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Clinical outcome (modified Rankin Scale scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomical pelvic organ prolapse stage II‐IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tumor conspicuity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 150-kDa ternary complex-associated IGFBP-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum IGF-I normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Leg swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iliac vein occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Multiple follicular development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Severe hyperstimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Coronary artery calcified plaque burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of life index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Daytime urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Arterial ammonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum endotoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetics and pharmacodynamics of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment ratio of warfarin co-administered with fesoterodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of concomitant administration of fesoterodine and warfarin
Endpoint domain: Adverse events/effects
Primary endpoint: combined complete plus partial responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUA symptom score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak flow rate change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BPH impact score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of tumor recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportional difference in improvement between BoNT and Placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median voids per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life parameters
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area of pinprick hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of mechanical hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold pain perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O(3)‐induced sputum neutrophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: airway‐specific serum biomarker Clara cell protein 16 (CCP16)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Survival Time (MST)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of infection complications (IC)
Endpoint domain: Mortality/survival
Primary endpoint: Cocaine-negative urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak systolic flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PROMIS Fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: skin surface pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: permeability barrier function (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: gingival health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood transfusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Left ventricular ejection fraction (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum ox‐LDL level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptom amelioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: improved social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Ownership of LLINs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Use of mosquito nets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination of tubal factor infertility from normal fertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Discrimination of acute infection from C trachomatis-exposed women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Inappropriate shock reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total time taken for procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total errors made
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: excess needle manipulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: markedly effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: C3 level stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: side effects occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: awakening signs arrival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ramsay score evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of oncomiRs and TSmiRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Receptive language skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary cannulation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of neglect in drawing/copying tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensation in the affected arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent dense mammographic area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric emptying improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of symptoms score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart-ankle pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cortisol area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum sodium concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in dyspnea
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pressure Pain Threshold (PPT) in the ipsilateral tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood to drink and binge drink
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood to experience alcohol harms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of stable angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total CHD incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of time with pH >4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median intragastric pH on day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median intragastric pH on day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: combined morbidity/mortality
Endpoint domain: Mortality/survival
Primary endpoint: Fracture pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Life expectancy (QALYs)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ECG changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Supine systolic blood pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antenatal outpatient clinic visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visits to maternal health centers
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: persistent rotator cuff defects after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Impaired restrictive pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean analgesic intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean VAS value at 4th postoperative hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast agent reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rates at six months
Endpoint domain: Mortality/survival
Primary endpoint: incidence of symptomatic ICH
Endpoint domain: Adverse events/effects
Primary endpoint: Inhibition of capsaicin-induced increases in DBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental area under the response curve for insulin (iAUC(insulin))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incremental area under the response curve for C-peptide (iAUC(C-peptide))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incremental area under the response curve for glucose (iAUC(glucose))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Febrile Neutropenia (FN) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CFR (Coronary Flow Reserve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in analogue score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical intracanal bacterial reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to normalisation of respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: time to normalisation of oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximal exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leftover medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: likelihood of still taking opioid at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes